Sinovac Biotech revamps controversial take-private

Beset by long-running activist investor concerns and legal issues – not least bribery concerns – the biopharmaceutical products manufacturer has upped its de-listing offer.

Sinovac Biotech has upped its offer to de-list from Nasdaq almost 17 months after it first tried to go private, in a deal that values the firm at around $401.8 million. But it could still have its work cut out to get the deal done given ongoing pricing disputes and bribery concerns. 

According to a filing to the US Securities and Exchange Commission SEC on Monday, parent entity Sinovac Cayman Limited will acquire the biopharmaceutical products provider for a cash consideration of $7 per common share. A consortium comprising Yin Weidong, chairman, president and chief executive officer of Sinovac Biotech, SAIF Softbank Asia Infrastructure Fund Partners, C-Bridge Capital, Advantech...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222